CT-1-CP-induced ventricular electrical remodeling in mice

Abstract

The chronic effects of carboxyl-terminal polypeptide of Cardiotrophin-1 (CT-1-CP) on ventricular electrical remodeling were investigated. CT-1-CP, which contains 16 amino acids in sequence of the C-terminal of Cardiotrophin-1, was selected and synthesized, and then administered to Kunming mice (aged 5 weeks) by intraperitoneal injection (500 ng·g⁻¹·day⁻¹) (4 groups, n=10 and female: male=1:1 in each group) for 1, 2, 3 and 4 weeks, respectively. The control group (n=10, female: male=1:1) was injected by physiological saline for 4 weeks. The epicardial monophasic action potential (MAP) was recorded by using a contact-type MAP electrode placed vertically on the left ventricular (LV) epicardium surface, and the electrocardiogram (ECG) signal in lead II was monitored synchronously. ECG intervals (RR, PR, QRS and QT) and the amplitude of MAP (Am), the maximum upstroke velocity (Vmax), as well as action potential durations (APDs) at different repolarization levels (APD₃₀, APD₅₀, APD₇₀, and APD₉₀) of MAP were determined and analyzed in detail. There were no significant differences in RR and P intervals between CT-1-CP-treated groups and control group, but the PR segment and the QRS complex were greater in the former than in the latter (F=2.681 and 5.462 respectively, P<0.05). Though QT interval and the corrected QT interval (QTc) were shorter in CT-1-CP-treated groups than in control group, the QT dispersion (QT_d) of them was greater in the latter than in the former (F=3.090, P<0.05) and increased with the time. The ECG monitoring synchronously with the MAP showed that the compression of MAP electrode on the left ventricular epicardium induced performance similar to myocardium ischemia. As compared with those before chest-opening, the PR segment and QT intervals remained basically unchanged in control group, but prolonged significantly in all CT-1-CP-treated groups and the prolongation of QT intervals increased gradually along with the time of exposure to CT-1-CP. The QRS complex had no significant change in control group, one-week and three-week CT-1-CP-treated groups, but prolonged significantly in two-week and four-week CT-1-CP-treated groups. Interestingly, the QT_d after chest-opening was significantly greater than that before chest-opening in control group (t=5.242, P<0.01), but decreased along with the time in CT-1-CP-treated groups. The mean MAP amplitude, Vmax and APD were greater in CT-1-CP-treated groups than those in control group, and became more obvious along with the time. The APD in four CT-1-CP-treat groups was prolonged mainly in middle to final repolarization phase. The difference among these groups became significant in middle phase (APD₅₀) (F=6.076, P<0.01) and increased furthermore in late and final phases (APD₇₀: F=10.054; APD₉₀: F=18.691, P<0.01) along with the time of injection of CT-1-CP. The chronic action of CT-1-CP might induce the adapting alteration in cardiac conductivity and ventricular repolarization. The amplitude and the Vmax of the anterior LV epicardial MAP increased obviously, and the APD prolonged mainly in late and final phase of repolarization.

Keywords

carboxyl-terminal polypeptide of cardiotrophin-1 / monophasic action potential / action potential duration / electrical remodeling

References

[1] PennicaD, KingKL, ShawKJ, et al. . Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy. Proc Natl Acad Sci USA, 1995, 92(4): 1142-1146 PMCID: 42654 PMID: 7862649

[2] FreedDH, CunningtonRH, DangerfieldAL, et al. . Emerging evidence for the role of cardiotrophin-1 in cardiac repair in the infarcted heart. Cardiovasc Res, 2005, 65(4): 782-792 PMID: 15721858

[3] LópezB, GonzálezA, LasarteJJ, et al. . Is plasma cardiotrophin-1 a marker of hypertensive heart disease?. J Hypertens, 2005, 23(3): 625-632 PMID: 15716706

[4] CelikA, SahinS, KocF, et al. . Cardiotrophin-1 plasma levels are increased in patients with diastolic heart failure. Med Sci Monit, 2012, 18(1): CR25-CR31 PMCID: 3560678 PMID: 22207116

[5] DrobicV, CunningtonRH, BedoskyKM, et al. . Differential and combined effects of cardiotrophin-1 and TGF-beta1 on cardiac myofibroblast proliferation and contraction. Am J Physiol Heart Circ Physiol, 2007, 293(2): H1053-H1064 PMID: 17483238

[6] TurnerNA, DasA, WarburtonP, et al. . Interleukin-1alpha stimulates proinflammatory cytokine expression in human cardiac myofibroblasts. Am J Physiol Heart Circ Physiol, 2009, 297(3): H1117-H1127 PMID: 19648252

[7] YaoZ, ChenSF, LinQY, et al. . Effects of cardiotrophin-1 C-terminal peptides on rats following myocardial ischemia reperfusion injury. Lingnan Xinxueguanbing Zazhi (Chinese), 2008, 14(3): 211-214

[8] ChenSF, YaoZ, ZhangXF. Influence of cardiotrophin-1 C-terminal peptides on ECG in rats following myocardial ischemia reperfusion injury. Lingnan Xinxueguanbing Zazhi (Chinese), 2008, 17(6): 442-445

[9] FranzMR. Current status of monophasic action potential recording: theories, measurements and interpretations. Cardiovasc Res, 1999, 41(1): 25-40 PMID: 10325951

[10] ArmoundasAA, WuR, JuangG, et al. . Electrical and structural remodeling of the failing ventricle. Pharmacol Ther, 2001, 92(2–3): 213-230 PMID: 11916538

[11] EverettTH4th, OlginJE. Atrial fibrosis and the mechanisms of atrial fibrillation. Heart Rhythm, 2007, 4(3Suppl): S24-S27 PMCID: 1850572 PMID: 17336879

[12] WollertKC, TagaT, SaitoM, et al. . Cardiotrophin-1 activates a distinct form of cardiac muscle cell hypertrophy. Assembly of sarcomeric units in series VIA gp130/leukemia inhibitory factor receptor-dependent pathways. J Biol Chem, 1996, 271(19): 9535-9545 PMID: 8621626

[13] FreedDH, ChiltonL, LiY, et al. . Role of myosin light chain kinase in cardiotrophin-1-induced cardiac myofibroblast cell migration. Am J Physiol Heart Circ Physiol, 2011, 301(2): H514-H522 PMID: 21572008

[14] QuYH, LeungKP, QiaoDF, et al. . Remodeling of ion channel expression may contribute to electrophysiological consequences caused by methamphetamine in vitro and in vivo. Biochem Biophys Res Commun, 2014, 443(2): 441-446 PMID: 24326070

[15] KnollmannBC, SchoberT, PetersenAO, et al. . Action potential characterization in intact mouse heart: steady-state cycle length dependence and electrical restitution. Am J Physiol Heart Circ Physiol, 2007, 292: H614-H621 PMID: 16963611

[16] GuoW, JungWE, MarionneauC, et al. . Targeted deletion of Kv4.2 eliminates Ito, fand results in electrical and molecular remodeling, with no evidence of ventricular hypertrophy or myocardial dysfunction. Circ Res, 2005, 97: 1342-1350 PMID: 16293790

[17] BrunetS, AimondF, LiH, et al. . Heterogeneous expression of repolarizing, voltage-gated K⁺ currents in adult mouse ventricles. J Physiol, 2004, 559: 103-120 PMCID: 1665075 PMID: 15194740

[18] KnollmannBC, KirchhofP, SirenkoSG, et al. . Familial hypertrophic cardiomyopathy-linked mutant troponin T causes stress-induced ventricular tachycardia and Ca²⁺-dependent action potential remodeling. Circ Res, 2003, 92(4): 428-436 PMID: 12600890